Toll-Like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Yu, Hui ^a,c   Jin, Hongwei ^b   Sun, Lidan ^b   Zhang, Liangren ^b   Sun, Gang ^c   Wang, Zhanli ^c   Yu, Yongchun ^a  

^a TONGJI UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c BAOTOU MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BINDING SITE; COMPUTER PROGRAM; DRUG IDENTIFICATION; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; MOLECULAR INTERACTION; PHARMACOPHORE; RELIABILITY; SEQUENCE ALIGNMENT; VALIDATION PROCESS;

ALGORITHMS; AMINO ACID SEQUENCE; COMPUTER SIMULATION; DATABASES, CHEMICAL; DRUG DESIGN; DRUGS, CHINESE HERBAL; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; STRUCTURAL HOMOLOGY, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 7;

EID: 84875132782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056514     Document Type: Article

References (34)

1. Akira S, Uematsu S, Takeuchi O, (2006) Pathogen recognition and innate immunity. Cell 124: 783-801.
2. Kawai T, Akira S, (2007) TLR signaling. Semin Immunol 19: 24-32.
3. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, et al. (2004) Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A 101: 3516-3521.
4. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, et al. (2007) Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 7: 1271-1285.
5. Yu H, Wang Z, Sun G, Yu Y, (2012) Recognition of nucleic acid ligands by Toll-like receptors 7/8: importance of chemical modification. Curr Med Chem 19: 1365-1377.
6. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, et al. (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3: 196-200.
7. Lee J, Chuang TH, Redecke V, She L, Pitha PM, et al. (2003) Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of toll-like receptor 7. Proc Natl Acad Sci U S A 100: 6646-6651.
8. Akira S, Hemmi H, (2003) Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85: 85-95.
9. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, et al. (2003) The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 33: 2987-2997.
10. Jones P, Pryde C (2006) 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C. WO 2006/117670.
11. Jones P, Pryde C, Tran T (2007) 3-deazapurine derivatives as TLR7 modulators. WO 2007/09301.
12. Chong L, Desai M, Gallagher B, Graupe M, Halcomb R, et al. (2008) Modulators of toll-like receptor 7. WO 2008/05555.
13. Cook A, Mcinally T, Thom S, Wada H (2008) 8-oxoadenine derivatives acting as modulators of TLR7. WO 2008/004948.
14. Kurimoto A, Hashimoto K, Nakamura T, Norimura K, Ogita H, et al. (2010) Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept. J Med Chem 53: 2964-2972.
15. Pryde DC, Tran TD, Jones P, Parsons GC, Bish G, et al. (2011) The discovery of a novel prototype small molecule TLR7 agonist for the treatment of hepatitis C virus infection. Med Chem Commun 2: 185-189.
16. Tran TD, Pryde DC, Jones P, Adam FM, Benson N, et al. (2011) Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection. Bioorg Med Chem Lett 21: 2389-2393.
17. Jones P, Pryde DC, Tran TD, Adam FM, Bish G, et al. (2011) Discovery of a highly potent series of TLR7 agonists. Bioorg Med Chem Lett 21: 5939-5943.
18. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, et al. (2007) Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 47: 174-182.
19. Traditional Chinese Medicine Database (TCMD), Accelrys Inc., Beijing, Chinese edition, 2005. Available: http://www.neotrident.com/newpage/show_page.asp?ArticleID=973& ClassID = 112&GroupID = 26.
20. Li H, Sutter J, Hoffmann R (2000) HypoGen: an automated system for generating predictive 3D pharmacophore models. In: Güner OF, editors. Pharmacophore Perception, Development, and use in Drug Design. La Jolla: International University Line. PP: 173-189.
21. Wei T, Gong J, Jamitzky F, Heckl WM, Stark RW, (2009) Homology modeling of human Toll-like receptors TLR7, 8, and 9 ligand-binding domains. Protein Sci 18: 1684-1691.
22. Gong J, Wei T, Zhang N, Jamitzky F, Heckl WM, et al. (2010) TollML: a database of toll-like receptor structural motifs. J Mol Model 16: 1283-1289.
23. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
24. Laskoswki RA, MacArthur MW, Moss DS, Thorton JM, (1993) PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Cryst 26: 283-291.
25. Colovos C, Yeates TO, (1993) Verification of protein structures: Patterns of nonbonded atomic interactions. Protein Sci 2: 1511-1519.
26. Chen R, Weng ZP, (2002) Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins 47: 281-294.
27. Venkatachalam CM, Jiang X, Oldfield T, Waldman M, (2003) LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 21: 289-307.
28. Diller DJ, Merz KM Jr, (2001) High throughput docking for library design and library prioritization. Proteins 43: 113-124.
29. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, et al. (2008) The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456: 658-662.
30. Iavarone C, Ramsauer K, Kubarenko AV, Debasitis JC, Leykin I, et al. (2011) A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. J Immunol 186: 4213-4222.
31. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, (2005) The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci U S A 102: 9577-9582.
32. Govindaraj RG, Manavalan B, Basith S, Choi S, (2011) Comparative analysis of species-specific ligand recognition in toll-like receptor 8 signaling: a hypothesis. PLoS One 6: e25118.
33. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, et al. (2004) Toll-like receptor 9 binds singlestranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 34: 2541-2550.
34. Gibbard RJ, Morley PJ, Gay NJ, (2006) Conserved features in the extracellular domain of human toll-like receptor 8 are essential for pH-dependent signaling. J Biol Chem 281: 27503-27511.